Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech. 

By agreeing to pay $7.3bn for Reata and its Friedrich’s ataxia drug Skyclarys, “recalibrating” Biogen can be more patient with launches of Alzheimer’s drug Leqembi and ALS therapy Qalsody.

With a platform of interesting preclinical assets and a Phase III-ready program from a collapsed biotech business, new company Beacon Therapeutics can claim unconventional origins. 

The UK firm’s substantial series A raise will help it advance a pipeline of gene therapy candidates for both rare and common retinal conditions, including a Phase II candidate rescued from a struggling biotech.